Multi-omics-derived immune-inflammatory biomarkers across disease trajectories

Immune and inflammatory responses evolve across disease onset, active injury, progression, remission, and relapse, yet most biomarker studies capture only a single time point. Genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiome profiling, and single-cell or spatial technologies now enable integrated characterization of these changing states. However, many reported signatures remain difficult to interpret or reproduce because their cellular and tissue origins are unclear, biospecimen compartments are not directly compared, and independent validation is limited. A trajectory-centered approach is therefore needed to distinguish transient inflammatory signals from stable disease endotypes and to identify biomarkers that can support diagnosis, prognosis, patient stratification, and treatment monitoring across diverse immune-mediated and inflammation-related disorders.This Research Topic aims to advance multi-omics-derived immune-inflammatory biomarkers from statistical association toward biological interpretation and clinical utility. We seek studies that connect biomarker signatures to defined immune-cell states, inflammatory pathways, tissue microenvironments, and mechanisms of organ injury or repair. Particular emphasis will be placed on longitudinal sampling and clinically meaningful transitions, including disease initiation, flare, progression, remission, recurrence, therapeutic response, resistance, and adverse immune effects. Recent advances in high-throughput molecular profiling, single-cell and spatial analysis, integrative computation, and minimally invasive sampling provide new opportunities to map these transitions with greater resolution. Contributions should address reproducibility through functional validation, external cohorts, prospective designs, or cross-platform replication, and should evaluate whether proposed markers add value beyond established clinical, imaging, and laboratory indicators.Within a broad cross-disease framework, we welcome Original Research, Reviews, Systematic Reviews, Methods, and Perspectives addressing:• Integration of genomic, epigenomic, transcriptomic, proteomic, metabolomic, lipidomic, microbiome, single-cell, spatial, imaging, or clinical data;• Biological and cellular origins of circulating, tissue-based, microbial, imaging, and composite immune-inflammatory biomarkers;• Longitudinal biomarkers of disease onset, activity, exacerbation, progression, remission, recurrence, and complications;• Diagnostic, prognostic, predictive, and pharmacodynamic biomarkers for disease endotyping, risk stratification, treatment selection, and response monitoring;• Concordance and discordance among blood, tissue, and other biospecimen compartments, including minimally invasive sampling;• Assay standardization, external validation, prospective evaluation, and demonstration of incremental clinical utility.Studies may address infectious, autoimmune, autoinflammatory, allergic, metabolic, cardiovascular, respiratory, neurological, hepatic, renal, malignant, or fibrotic diseases. Computational or public-dataset analyses should include independent biological or clinical validation.Studies using indexes based on simple blood cell count or biomarkers unrelated to immune cells or immunological mechanisms are out of scope for this journal. Topic editors: Daqing Wang, Sarfraz Ahmed, Aziz Ur Rehman Aziz, Adeela Saeed Source: https://www.frontiersin.org/research-topics/84675/multi-omics-derived-immune-inflammatory-biomarkers-across-disease-trajectories